Tricks behind Peter Horby’s conclusion of no beneficial effect of hydroxychloroquine for hospitalized patients with COVID-19

By Cuckoo (子规)

8 June, 2020

On June 5, 2020, Oxford professor Peter Horby said his large trial showed that hydroxychloroquine doesn’t reduce the risk of death among hospitalized patients with COVID-19. “This result should change medical practice worldwide. We can now stop using a drug that is useless,” Horby told the reporters.The trial gave hospitalized patients 2400 mg of hydroxychloroquine in first 24 hours, and 800 mg every day for 9 days.

Prior to his trial, several clinical studies had already demonstrated good virological and clinical outcomes with hydroxychloroquine alone (200-600 mg/day) or in combination with azithromycin in COVID-19 patients. They used much less dosage than Horby’s trial used.

Horby claimed his trial was the largest trial in the world so far. Why his trial didn’t include the dosage and treatment that already showed positive effects in small trial and great potential for wide usage of this cheap medicine?

Horby has been actively involved in virus research in China. He has published seven papers on viruses with Chinese scientists since 2014, funded by CPP, the Bill and Melinda Gates Foundation, and The National Institute of Allergy and Infectious Diseases (NIAID) NIH HHS.

He began working with CCP officials on COVID-19 since January 2, 2020, but didn’t alarm UK government in whole January, the very critical period for controlling the disease. At same time, he was working on the lopinavir-ritonavir trial and helping design a trial for remdesivir on COVID-19, sponsored by the Chinese government.

On 11 April 2020, as a top Government coronavirus adviser, his close link with China from the start of the coronavirus outbreak raised questions about whether he could have done more to raise the alarm in the UK. He should have done much better for whole world, as he has acted frequently as an advisor/consultant to the WHO.

Many left-leaning media applauded Horby’s conclusion.  They asserted that hydroxychloroquine is useless, ignoring the facts that hydroxychloroquine makes a positive difference as a preventative measure or as a treatment for patients with mild symptoms. They said that Horby’s conclusion is the biggest blow yet for the therapy touted by U.S. President Donald Trump.

On June 8, 2020, some pharmaceutical media also claimed that hydroxychloroquine is useless, and Horby’s findings appear to close the door on early hopes that hydroxychloroquine could offer a mitigating effect on the course of the disease or as a prophylactic.

Sources:

1. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. http://www.ox.ac.uk/news/2020-06-05-no-clinical-benefit-use-hydroxychloroquine-hospitalised-patients-covid-19.

2. RANDOMISED EVALUATION OF COVID-19 THERAPY. https://clinicaltrials.gov/ct2/show/NCT04381936.

3. Gautret et al. Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial medRxiv (2020) https://www.medrxiv.org/content/10.1101/2020.03.16.20037135v1

4. Gautret P, Lagier JC, Parolaet P et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Int J Antimicrob Agents. 2020 Mar 20:105949.

5. A Detailed Coronavirus Treatment Plan from Dr. Vladimir Zelenko https://internetprotocol.co/hype-news/2020/04/14/a-detailed-coronavirus-treatment-plan-from-dr-zelenko/.

6. https://www.sermo.com/press-releases/category/covid-19/.

7. Coronavirus: world’s biggest trial of drug to treat Covid-19 begins in UK. https://www.theguardian.com/world/2020/apr/17/world-biggest-drug-trial-covid-19-uk.

8.Wang C, Yu H, Horby P et al. Comparison of Patients Hospitalized With Influenza A Subtypes H7N9, H5N1, and 2009 Pandemic H1N1. Clinical Infectious Diseases 2014;58(8):1095–103.

9. Wang X et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis. 2017(8): 822–832. doi:10.1016/S1473-3099(17)30323-7.

10. Horby et al. Evaluation of the Efficacy and Safety of Intravenous Remdesivir in Adult Patients with Severe Pneumonia caused by COVID-19 virus Infection: study protocol for a Phase 3 Randomized, Double-blind,       Placebo-controlled, Multicentre trial. 2020.https://www.researchsquare.com/article/rs-14618/v2.

11. British government adviser who worked with China from the start of the coronavirus outbreak faces questions about whether he could have done more to raise the alarm in the UK. https://www.dailymail.co.uk/news/article-8211403/British-adviser-worked-China-start-coronavirus-outbreak-faces-questions.html.

12. Professor Peter Horby | University of Oxford. http://www.ox.ac.uk/news-and-events/find-an-expert/professor-peter-horby.

13. https://www.bloomberg.com/news/articles/2020-06-05/hydroxychloroquine-shows-no-covid-19-benefit-oxford-study-says-kb2c5cfm.

14. https://thefederal.com/health/hydroxychloroquine-useless-for-covid-19-treatment-oxford-prof/.

15. https://www.ctvnews.ca/health/coronavirus/no-benefit-from-hydroxychloroquine-for-virus-u-k-trial-1.4971222.

16. https://pharmaphorum.com/news/big-uk-trial-says-hydroxychloroquine-has-no-effect-on-covid-19/.

17. https://www.rehabpub.com/industry-news/research/hydroxychloroquine-is-a-dud/.

Picture 1
+1
2 Comments
Inline Feedbacks
View all comments
trackback
5 months ago

… [Trackback]

[…] Find More Info here to that Topic: gnews.org/227788/ […]

0
trackback

… [Trackback]

[…] Find More Information here on that Topic: gnews.org/227788/ […]

0